Evidence map›Paper›PMID 29867233›Full record

ArticleNature medicine2018

Impact of neutralizing antibodies against AAV is a key consideration in gene transfer to nonhuman primates.

Weidong Xiao, Guangping Gao, Chen Ling, Roland W Herzog, Xiao Xiao, Richard J Samulski

Abstract readLetterComment
In one paragraph

Article in Nature medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Immune Response Mechanisms against AAV Vectors in Animal Models.Molecular therapy. Methods & clinical development · 2020
    Review
  7. Article
  8. AAV Immunogenicity: A Matter of Sensitivity.Molecular therapy : the journal of the American Society of Gene Therapy · 2018
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Weidong XiaoSol Sherry Thrombosis Research Center, Temple University Medical School, Philadelphia, PA, USA. wxiao@temple.edu.ORCID http://orcid.org/0000-0003-4295-1536
Guangping GaoGene Therapy Center, University of Massachusetts Medical School, Worcester, MA, USA. guangping.gao@umassmed.edu.
Chen LingDivision of Cellular and Molecular Therapy, Department of Pediatrics, University of Florida, Gainesville, FL, USA. lingchen@peds.ufl.edu.ORCID http://orcid.org/0000-0003-1527-1471
Roland W HerzogDivision of Cellular and Molecular Therapy, Department of Pediatrics, University of Florida, Gainesville, FL, USA. rherzog@ufl.edu.
Xiao XiaoDivision of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. xxiao@email.unc.edu.
Richard J SamulskiDepartment of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. rjs@med.unc.edu.

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI David Darr · 1985 to 2026
$201.5M
Enhancing immune regulation in gene therapy for hemophiliaR01HL131093 · NHLBI · UNIVERSITY OF FLORIDA · PI Ype Peter De Jong, Roland W. Herzog · 2016 to 2026
$7.2M
Immunology of Factor IX Gene Transfer to LiverR01AI051390 · NIAID · UNIVERSITY OF FLORIDA · PI HERZOG, ROLAND W. · 2002 to 2022
$6.7M
Next Generation of Recombinant AAV Serotype Vectors for Gene TherapyR01HL097088 · NHLBI · UNIVERSITY OF FLORIDA · PI GAO, GUANGPING, HERZOG, ROLAND W. · 2010 to 2018
$5.4M
Molecular Biology of Recombinant AAV GenomesR01HL080789 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI XIAO, WEIDONG · 2006 to 2014
$3.1M
Development of highly efficient factor VIII mini-gene therapyR01HL130871 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI XIAO, WEIDONG · 2016 to 2019
$1.9M
Molecular engineering of factor VIII gene for rAAV deliveryR01HL084381 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI XIAO, WEIDONG · 2008 to 2012
$1.9M
Mechanism of high-efficiency transduction of hepatocytes by optimized AAV vectorsR01GM119186 · NIGMS · UNIVERSITY OF FLORIDA · PI ASLANIDI, GEORGE V, SRIVASTAVA, ARUN · 2017 to 2021
$1.5M
Molecular and Cellular Characterization of AAV1 VectorR01HL069051 · NHLBI · CHILDRENS HOSPITAL OF PHILADELPHIA · PI XIAO, WEIDONG · 2002 to 2005
$1.3M
NCI NIH HHS P30 CA016086NHLBI NIH HHS R01 HL069051NHLBI NIH HHS R01 HL080789NHLBI NIH HHS R01 HL084381NHLBI NIH HHS R01 HL097088NHLBI NIH HHS R01 HL130871NHLBI NIH HHS R01 HL131093NIAID NIH HHS R01 AI051390NIGMS NIH HHS R01 GM119186
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Non-alcoholic Fatty Liver DiseaseAnimalsAntibodies, NeutralizingApoptosisDependovirusFas-Associated Death Domain ProteinGenetic TherapyMicePrimatesAntibodies, NeutralizingFadd protein, mouseFas-Associated Death Domain Protein

Identifiers

PMID29867233
PMCPMC6290466

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.